reptides › weight loss › mazdutide

mazdutide

the GLP-1 + glucagon dual agonist approved in China. ~14% weight loss in GLORY-1 phase 3 at 48 weeks, ~20% at the higher dose. not FDA-approved.

tier A · weight loss · NMPA '25 approved in China

verdict

the glucagon/GLP-1 dual agonist that reached approval first, in China. real phase 3 efficacy, real label, but the pivotal data is single-ethnicity and there is no US approval.

if you're asking whether mazdutide works — yes, on a real phase 3 footing. GLORY-1, the pivotal Chinese obesity trial, reported about 14% mean weight loss at the 6 mg dose over 48 weeks (NEJM, 14.84% at 6 mg vs placebo), and the GLORY-2 program pushed the 9 mg dose to roughly 20.1%. Innovent and Eli Lilly developed it; China's NMPA approved it in 2025 for chronic weight management and type 2 diabetes. that is a higher bar than most pipeline peptides clear.

if you're asking why it's only an A and not an S — two things hold it back from the top band. the pivotal phase 3 efficacy was generated in a single-ethnicity Chinese population, so generalization to other populations is an open scientific question. and there is no US approval: a US phase 2 program exists (so the molecule is under active US investigation), but no US NDA has been filed or cleared. the efficacy is strong; the global evidence and regulatory base are narrower than tirzepatide or retatrutide.

if you came in worried about the glucagon arm — mazdutide is an oxyntomodulin analog: it hits the glucagon receptor as well as GLP-1, the same dual-mechanism logic that adds energy expenditure on top of appetite suppression. the trade is the familiar one for glucagon-containing agonists. heart rate and the hepatic axis warrant watching, and the long-term cardiovascular dataset outside the approved-in-China population is still thin. trial data to date did not surface a clinical surprise.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why A-tier

mazdutide clears a high bar: a pivotal phase 3 obesity readout (GLORY-1, ~14% at 6 mg over 48 weeks; ~20% at 9 mg in the GLORY-2 program) and a 2025 NMPA approval in China for chronic weight management and type 2 diabetes. that is real efficacy with a real label behind it. it lands at A rather than S because the pivotal efficacy was generated in a single-ethnicity Chinese population and there is no US approval, only an active US phase 2 program. strong dual-agonist data, narrower geographic and regulatory reach than the FDA-approved incretins.

the core tension

mazdutide is the GLP-1/glucagon dual agonist that beat the West to market. ~14% weight loss in GLORY-1, ~20% at the higher dose, and a real NMPA approval in China. the catch is reach, not mechanism: the pivotal efficacy is single-ethnicity Chinese data, and there is still no FDA approval. the story is about which dual agonist crossed the finish line first, and where it can be used.

what it is

An investigational-in-the-US, approved-in-China dual agonist. Activates the GLP-1 and glucagon receptors at once, built as an analog of oxyntomodulin, the gut hormone that naturally hits both. Developed by Innovent Biologics in partnership with Eli Lilly. Innovent code IBI362, Lilly code LY3305677. Unlike tirzepatide (GIP + GLP-1) or retatrutide (GIP + GLP-1 + glucagon), mazdutide pairs GLP-1 with glucagon and no GIP.

what it does

The GLP-1 arm delivers the class-standard satiety and glucose effects. The glucagon arm adds an energy-expenditure and hepatic-fat component the GIP-based drugs approach differently. GLORY-1 (phase 3, China): roughly 14% mean weight loss at the 6 mg dose over 48 weeks (NEJM reported 14.84% at 6 mg). The GLORY-2 program, testing the higher 9 mg dose, reported approximately 20.1% mean weight loss. China's NMPA approved mazdutide in 2025 for chronic weight management and for type 2 diabetes.

origin

Built by Innovent Biologics under a collaboration with Eli Lilly, originating from Lilly's oxyntomodulin-analog work (LY3305677). The strategic choice was glucagon instead of GIP: pair appetite-suppressing GLP-1 with glucagon's energy-expenditure and hepatic effects. The GLORY phase 3 program ran in China and supported the 2025 NMPA approvals. A US phase 2 program exists, which means the molecule is under active investigation in the US, but Innovent and Lilly have not secured a US approval and no US NDA clearance has been announced.

why researchers are interested

It is the dual GLP-1/glucagon agonist that actually reached approval, ahead of survodutide and the other glucagon-containing contenders. Roughly 14% to 20% weight loss across the dose range is squarely in modern-incretin territory. The peptide community watches it as proof that the GLP-1/glucagon mechanism (not just GIP/GLP-1) can clear a regulator, and as a preview of where the survodutide-style dual agonists are headed.

does it work

Yes on efficacy, with a geography caveat. The phase 3 data is real, not a projection: roughly 14% weight loss at 6 mg in GLORY-1 and about 20% at the 9 mg dose in GLORY-2, and a Chinese regulatory approval to back it. The open questions are about reach, not whether it works. The pivotal efficacy was generated in a single-ethnicity Chinese population, and there is no FDA approval, only a US phase 2 program in progress. The mechanism and the numbers are sound. The global evidence base and the regulatory base are narrower than the FDA-approved incretins.

claims vs the data

  • approved weight loss drug — supported — NMPA-approved in China in 2025 for chronic weight management and type 2 diabetes. real regulatory clearance, not a projection.
  • ~14% weight loss in phase 3 — supported — GLORY-1 reported about 14.84% mean weight loss at the 6 mg dose over 48 weeks (NEJM).
  • reaches ~20% at the higher dose — supported — the GLORY-2 program at the 9 mg dose reported roughly 20.1% mean weight loss.
  • glucagon agonism adds energy expenditure — supported — mazdutide is an oxyntomodulin analog; the glucagon arm contributes the energy-expenditure and hepatic component on top of GLP-1.
  • as broadly proven as tirzepatide or semaglutide — contradicted — the pivotal efficacy is single-ethnicity Chinese data and there is no FDA approval. the global evidence and regulatory base are narrower.
  • FDA-approved — contradicted — not FDA-approved. a US phase 2 program exists (active US investigation), but no US NDA has cleared.
  • a GIP-containing drug like tirzepatide — contradicted — mazdutide is GLP-1 + glucagon, no GIP. the GIP-containing drugs are tirzepatide (GIP/GLP-1) and retatrutide (triple).

key facts

  • molecular formula: C₂₁₀H₃₂₂N₄₆O₆₇
  • molecular weight: ~4563 g/mol
  • amino acids: 33
  • half-life: ~once-weekly dosing
  • type: GLP-1/glucagon dual agonist
  • CAS: 2259884-03-0
  • ~14% avg weight loss, 48wk · 6mg (GLORY-1)
  • ~20% avg weight loss, 9mg (GLORY-2 program)
  • NMPA '25 approved in China
  • phase 2 US program (not FDA-approved)

frequently asked questions

What is mazdutide?

Mazdutide is a GLP-1 and glucagon receptor dual agonist, built as an analog of the gut hormone oxyntomodulin. It was developed by Innovent Biologics in collaboration with Eli Lilly (codes IBI362 and LY3305677) and is approved in China for chronic weight management and type 2 diabetes.

What does mazdutide do?

Mazdutide activates the GLP-1 receptor (slows digestion and suppresses appetite) and the glucagon receptor (adds an energy-expenditure and hepatic-fat component). In the pivotal Chinese phase 3 trial GLORY-1, the 6 mg dose produced about 14% mean weight loss over 48 weeks; the higher 9 mg dose in the GLORY-2 program reached roughly 20%.

How does mazdutide work?

Mazdutide is an oxyntomodulin analog, so it engages two receptors at once: GLP-1 for appetite suppression and glucose control, and glucagon for increased energy expenditure and hepatic fat handling. Unlike tirzepatide (GIP + GLP-1), it pairs GLP-1 with glucagon rather than GIP, attacking weight from both intake and expenditure.

How is mazdutide typically administered?

In the Chinese clinical program mazdutide is given as a once-weekly subcutaneous injection with stepwise dose titration (commonly toward a 4, 6, or 9 mg target dose). It is not available by US prescription as of 2026.

What are the side effects of mazdutide?

Reported side effects in trials are primarily gastrointestinal, nausea, diarrhea, decreased appetite, consistent with the GLP-1 drug class. The glucagon component adds attention to heart rate and hepatic measures, which were monitored across the GLORY program.

Is mazdutide FDA approved?

No. Mazdutide is approved in China by the NMPA (2025) for chronic weight management and type 2 diabetes, but it is not FDA-approved. A US phase 2 program exists, so the molecule is under active US investigation, but no US NDA has cleared.

How is mazdutide different from retatrutide and tirzepatide?

All three are multi-receptor incretin agonists, but the receptor combinations differ. Tirzepatide is GIP + GLP-1, retatrutide is GIP + GLP-1 + glucagon, and mazdutide is GLP-1 + glucagon (no GIP). Mazdutide is the GLP-1/glucagon dual agonist that reached approval first, in China, ahead of survodutide.

How much does mazdutide cost?

Mazdutide is sold by prescription in China; no US retail price exists because it is not FDA-approved. On the research-chemical market it tends to price alongside other modern incretin peptides.

related peptides

  • survodutide — the other GLP-1/glucagon dual agonist, still in phase 3
  • retatrutide — triple agonist that adds GIP on top of the GLP-1/glucagon pair
  • tirzepatide — GIP/GLP-1 dual agonist benchmark

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.